BioMarin Pharmaceutical
E917097
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
All labels observed (2)
| Label | Occurrences |
|---|---|
| BioMarin | 1 |
| BioMarin Pharmaceutical canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11306661 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: BioMarin Pharmaceutical Context triple: [Novato, California, hasEmployer, BioMarin Pharmaceutical]
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Amgen
Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
-
C.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
D.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: BioMarin Pharmaceutical Target entity description: BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Amgen
Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
-
C.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
D.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
public company ⓘ |
| businessModel |
commercialization of rare disease therapies
ⓘ
research and development of enzyme replacement therapies ⓘ |
| coDeveloped | Aldurazyme ⓘ |
| coDevelopedWith | Genzyme ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| developsTreatmentFor |
CLN2 disease
ⓘ
achondroplasia ⓘ mucopolysaccharidosis I ⓘ mucopolysaccharidosis IVA ⓘ mucopolysaccharidosis VI ⓘ phenylketonuria ⓘ |
| focusesOn | orphan drugs ⓘ |
| foundedBy |
Alejandro Zaffaroni
ⓘ
Christopher Starr ⓘ Grant W. Denison Jr. ⓘ |
| hasAbbreviation |
BioMarin
ⓘ
linked to:
BioMarin Pharmaceutical
|
| hasCollaboration | Genzyme ⓘ |
| hasOfficialWebsite | https://www.biomarin.com/ ⓘ |
| hasProduct |
Aldurazyme
ⓘ
Brineura ⓘ Kuvan ⓘ Naglazyme ⓘ Palynziq ⓘ Vimizim ⓘ Voxzogo ⓘ |
| hasResearchFocus |
enzyme replacement therapy
ⓘ
gene therapy ⓘ |
| hasTherapeuticArea |
lysosomal storage disorders
ⓘ
metabolic disorders ⓘ neurological rare diseases ⓘ skeletal dysplasias ⓘ |
| headquartersLocation |
San Rafael, California
ⓘ
linked to:
San Rafael
|
| inception | 1997 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| languageOfWorkOrName | English ⓘ |
| legalForm | corporation ⓘ |
| listedIn |
NASDAQ Biotechnology Index
ⓘ
linked to:
Nasdaq Biotechnology Index
|
| operatesIn |
Asia
ⓘ
Europe ⓘ North America ⓘ |
| regulatoryFocus | orphan drug designation ⓘ |
| specializesIn | therapies for rare genetic diseases ⓘ |
| stockExchange | NASDAQ ⓘ |
| targetMarket | patients with rare genetic disorders ⓘ |
| tickerSymbol | BMRN ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: BioMarin Pharmaceutical Description of subject: BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
Novato, California, United States
linked to: BioMarin Pharmaceutical